Cardiovascular disease (CVD) is the number one killer of American men and women, and its economic burden is substantial and on the rise. Adults with depression are at elevated risk of CVD events and poor CVD prognosis. Unfortunately, past trials of depression treatments have not observed the anticipated cardiovascular benefits. A novel explanation for these null results is that the interventions in these trials, which all involved patients with preexisting CVD, were delivered too late in the natural history of CVD. To begin to evaluate our hypothesis that treating depression before clinical CVD onset could reduce CVD risk, we conducted an 8-year follow-up study of a positive depression trial, the IMPACT trial. Intervention patients without baseline CVD had a 48% lower risk of fatal/nonfatal myocardial infarction or stroke than did usual care patients. Although these results support our hypothesis, they are post hoc and observational, CVD outcomes were not pre-specified endpoints, and minimal mechanistic data was collected. To address the current need for a well-powered, prospective trial, we propose a Phase 2 randomized controlled trial of 216 primary care patients (=50 years, 60% female, 40% African American, 5% Latino) with a depressive disorder and elevated CVD risk but no clinical CVD. Patients will be randomized to one year of eIMPACT, our modernized version of the IMPACT intervention, or usual care. eIMPACT is a collaborative stepped care intervention involving a multidisciplinary team delivering evidenced-based depression treatments consistent with patient preference. We will modernize our intervention by incorporating computerized cognitive-behavioral therapy and delivering other treatment components via telephone. Our central hypothesis is that eIMPACT will improve endothelial dysfunction, which is considered a barometer of CVD risk, in depressed adults by decreasing autonomic dysfunction, systemic inflammation, and platelet activation. We will test our central hypothesis by carrying out these specific aims: (1) to determine whether eIMPACT reduces the excess CVD risk of depressed patients (primary outcome: endothelial dysfunction; exploratory outcome: incident CVD events) and (2) to examine candidate mechanisms underlying the effect of eIMPACT on CVD risk (secondary outcomes: markers of autonomic dysfunction, systemic inflammation, and platelet activation). A positive trial would generate the mechanistic rationale, efficacy evidence, and effect size estimates that are needed to justify and design a multisite, event-driven Phase 3 trial to confirm eIMPACT's efficacy in reducing CVD risk. Demonstrating that depression treatment reduces CVD risk, the primary expected outcome of this line of research, would have a substantial positive impact. It would identify a novel treatment target (depression) for CVD prevention efforts, and it would equip providers with a new disseminable and scalable tool (eIMPACT) to simultaneously treat depression and manage CVD risk of a large cohort of high-risk patients. Collectively, these changes to clinical practice should translate into reduced CVD morbidity, mortality, and costs.
Depressed adults represent a large group of patients at elevated risk of cardiovascular disease (CVD) onset, poor prognosis, and high healthcare costs. This clinical trial will determine whether a modernized depression intervention called eIMPACT reduces the risk of CVD among older depressed patients with CVD risk factors. Showing that treating depression reduces the risk of CVD, the leading killer of Americans, would identify a novel treatment target (depression) for CVD prevention efforts and would equip providers with a new tool (eIMPACT) to manage the CVD risk of their patients, which should reduce CVD morbidity, mortality, and costs.
| Patel, Jay S; Berntson, Jessica; Polanka, Brittanny M et al. (2018) Cardiovascular Risk Factors as Differential Predictors of Incident Atypical and Typical Major Depressive Disorder in US Adults. Psychosom Med 80:508-514 |
| Case, Stephanie M; Sawhney, Manisha; Stewart, Jesse C (2018) Atypical depression and double depression predict new-onset cardiovascular disease in U.S. adults. Depress Anxiety 35:10-17 |
| Nurnberger Jr, John I (2017) A Genetic Locus Associated With Depression: The Iceberg Begins to Melt. Biol Psychiatry 82:304-305 |
| Berntson, Jessica; Patel, Jay S; Stewart, Jesse C (2017) Number of recent stressful life events and incident cardiovascular disease: Moderation by lifetime depressive disorder. J Psychosom Res 99:149-154 |
| Polanka, Brittanny M; Vrany, Elizabeth A; Patel, Jay et al. (2017) Depressive Disorder Subtypes as Predictors of Incident Obesity in US Adults: Moderation by Race/Ethnicity. Am J Epidemiol 185:734-742 |
